Summary
Serotonin released from aggregating platelets can reach sufficient concentrations to affect local vascular function in a number of ways. The monoamine can cause contraction of blood vessels by its direct action on smooth muscle or by potentiating the effect of other vasoconstrictor agents. It can also induce vasodilatation by a direct relaxing effect on smooth muscle, by inhibition of adrenergic nerves, and by release of an uncharacterised relaxing factor from endothelial cells. One of its most likely physiological roles is to aid in haemostasis by promoting platelet aggregation and by causing local vasoconstriction at sites of injury. It probably has a role in some forms of vascular pathology as well: it may contribute to vasospasm of cerebral, coronary, and digital arteries, particularly if there is endothelial dysfunction or damage.
Much evidence has implicated serotonin (5-hydroxytryptamine) in the pathogenesis of migraine. Serotonergic agonists, such as ergotamine, and antagonists, such as methys-ergide and pizotifen, are both used in therapy of migraine. Promising but conflicting early results have not yet defined a place for serotonergic antagonists in other vasospastic disorders. The antihypertensive efficacy of one serotonergic antagonist, ketanserin, raises questions about the possible involvement of serotonin in either the initiation or the maintenance of the elevated peripheral vascular resistance in several forms of hypertension, including essential hypertension.
Similar content being viewed by others
References
Ahlman H, Bhargava HN, Donahue PE, Newson B, Das Gupta TK, et al. The vagal release of 5-hydroxytryptamine from enterochromaffin cells in the cat. Acta Physiologica Scandinavica 104: 262–270, 1978
Allen GS, Gold LHA, Chou SN, French LA. Cerebral arterial spasm. Part 3: In vivo intracisternal production of spasm by serotonin and blood and its reversal by phenoxybenzamine. Journal of Neurosurgery 40: 451–458, 1974c
Allen GS, Gross CJ, French LA, Chou SN. Cerebral arterial spasm. Part 5: In vitro contractile activity of vasoactive agents including human CSF on human basilar and anterior cerebral arteries. Journal of Neurosurgery 44: 594–600, 1976
Allen GS, Henderson LM, Chou SN, French LA. Cerebral arterial spasm. Part I: in vitro contractile activity of vasoactive agents on canine basilar and middle cerebral arteries. Journal of Neurosurgery 40: 433–441, 1974a
Allen GS, Henderson LM, Chou SN, French LA. Cerebral arterial spasm. Part 2: In vitro contractile activity of serotonin in human serum and CSF on the canine basilar artery, and its blockage by methylsergide and phenoxybenzamine. Journal of Neurosurgery 40: 442–450, 1974b
Amery A, Fagard R, Fiocchi R, Lijnen P, Staessen J, et al. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients. Journal of Cardiovascular Pharmacology 6: 182–185, 1984
Andren L, Svensson A, Dahlof B, Eggertsen R, Hansson L. Ketanserin in hypertension. Acta Medica Scandinavica 214: 125–130, 1983
Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Archives of Neurology 16: 544–552, 1967
Astrom A, Samelius U. The action of 5-hydroxytryptamine and some of its antagonists on the umbilical vessels of the human placenta. British Journal of Pharmacology 12: 410–414, 1957
Beale G, Bogaerts H, Clement DL, Pannier R, Barbier F. Platelet activation during treadmill exercise in patients with chronic peripheral arterial disease. Thrombosis Research 23: 215–223, 1981
Boullin DJ. Recent advances in vasospasm research. In Boullin DJ (Ed.) Cerebral Vasospasm, pp. 293–299, John Wiley and Sons, Chichester, 1980
Boullin DJ, Mohan J, Grahame-Smith DG. Evidence for the presence of a vasoactive substance (possibly involved in the aetiology of cerebral arterial spasm) in cerebrospinal fluid from patients with subarachnoid haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry 39: 756–766, 1976
Bove AA, Dewey JD. Effects of serotonin and histamine on proximal and distal coronary vasculature in dogs: comparison with alpha-adrenergic stimulation. American Journal of Cardiology 52: 1333–1339, 1983
Brazenor RM, Angus JA. Ergometrine contracts isolated canine coronary arteries by a serotonergic mechanism: no role for alpha adrenoceptors. Journal of Pharmacology and Experimental Therapeutics 218: 530–536, 1981
Brazenor RM, Angus JA. Actions of serotonin antagonists on dog coronary artery. European Journal of Pharmacology 81: 569–576, 1982
Brown H. Serotonin-producing tumors. In Essman (Ed.) Serotonin in Health and Disease, pp. 393–423, Spectrum, New York, 1977
Buccino RA, Covell JA, Sonnenblick EH, Braunwald E. Effects of serotonin on the contractile state of the myocardium. American Journal of Physiology 213: 483–486, 1967
Burks TF, Long JP. 5-Hydroxytryptamine release into dog intestinal vasculature. American Journal of Physiology 211: 619–625, 1966
Chahine RA, Raizner AE, Luchi RJ. Coronary arterial spasm in classic angina pectoris. Catheterization and Cardiovascular Diagnosis 1: 337–342, 1975
Chand N, Altura BM. Serotonin receptors subserve only contraction in canine and rat pulmonary arteries and veins. Artery 7: 232–245, 1980
Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 305: 627–630, 1983
Cohen ML, Fuller RW, Kurz KD. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension 5: 676–681, 1983
Cohen RA, Coffman JD. Digital vasospasm: the pathophysiology of Raynaud’s phenomenon. International Angiology 3: 47–55, 1984
Cohen RA, Shepherd JT, Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 221: 273–274, 1983a
Cohen RA, Shepherd JT, Vanhoutte PM. 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. American Journal of Physiology 245: H1077–H1080, 1983b
Collis MG, Vanhoutte PM. Vascular reactivity of isolated perfused kidneys from male and female spontaneously hypertensive rats. Circulation Research 41: 759–767, 1977
Cortellaro M, Boschetti C, Antoniazzi V, Moreo G, Repetto S, et al. Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis — effect of sulphinpyrazone treatment. Thrombosis and Haemostasis 50: 857–859, 1983
Crawford NV. Systemic venous platelet-bound and plasma free serotonin levels in non-carcinoid malignancy. Clinica Chimica Acta 12: 274–281, 1965
Curro FA, Greenberg S, Verbeuren TJ, Vanhoutte PM. Interaction between alpha adrenergic and serotonergic activation of canine saphenous veins. Journal of Pharmacology and Experimental Therapeutics 207: 936–949, 1978
Curry RC, Pepine CJ, Sabom MB, Conti CR. Similarities of ergonovine-induced and spontaneous attacks of variant angina. Circulation 59: 307–312, 1979
De Clerck F, Van Nueten JM. Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin. Thrombosis Research 27: 713–727, 1982
De Clerck F, David J-L, Janssen PAJ. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R41468), a selective 5-HT2-receptor antagonist. Agents and Actions 12: 388–397, 1982
De Cree J, Leempoels J, Geukens H, De Cock W, Verhaegen H. The antihypertensive effects of ketanserin (R41468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension. Clinical Science 61: 473s–476s, 1981a
De Cree J, Leempoels J, De Cock W, Geukens H, Verhaegen H. The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R41468) in elderly patients. Angiology 32: 137–144, 1981b
De La Lande IS, Cannell VA, Waterson JC. The interaction of serotonin and noradrenaline on the perfused artery. British Journal of Pharmacology 28: 255–272, 1966
De Mey C, Vanhoutte PM. Effect of age and spontaneous hypertension on the tachyphylaxis to 5-hydroxytryptamine and angiotensin II in the isolated rat kidney. Hypertension 3: 718–724, 1981
De Roose J, Symoens J. Ketanserin in acute superficial thrombophlebitis. Lancet 2: 440–441, 1982
Degli Uberti EC, Trasforini G, Margutti AR, Rotola CA, Pansini R. Effect of ketanserin, a new inhibitor of 5-HT2 receptors, on plasma renin activity and aldosterone levels in normal subjects. Hormone Research 16: 244–248, 1982
Edvinsson L, Hardebo JE, Owman C. Pharmacological analysis of 5-hydroxytryptamine receptors in isolated intracranial and extracranial vessels of cat and man. Circulation Research 42: 143–151, 1978
Edvinsson L, Degueurce A, Duverger D, MacKenzie ET, Scatton B. Central serotonergic nerves project to the pial vessels of the brain. Nature 306: 55–57, 1983
Engbaek F, Voldby B. Radioimmunoassay of serotonin (5-hydroxytryptamine) in cerebrospinal fluid, plasma, and serum. Clinical Chemistry 28: 624–628, 1982
Engel G, Gothert M, Muller-Schweinitzer E, Schlicker E, Sistonen L, et al. Evidence for common pharmacological properties of 3H-5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Nau-nyn-Schmiedeberg’s Archives of Pharmacology 324: 116–124, 1983
Epstein S, Hamilton S. Cyproheptadine inhibition of stimulated plasma renin activity. Journal of Clinical Endocrinology and Metabolism 45: 1235–1237, 1977
Erspamer V. Recent research in the field of 5-hydroxytryptamine and related indolealkylamines. In Jucker E (Ed.) Progress in Drug Research, pp. 151–331, Interscience Publishers, New York, 1961
Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 169: 800–801, 1952
Fagard R, Cattaert A, Lijnen P, Staessen J, Vanhees L, et al. Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man. Clinical Science 66: 17–25, 1984
Fanchamps A. The evolution of thinking about the role and site of action of serotonin in migraine. In Critchley (Ed.) Advances in Neurology, Vol. 33. Headache: physiopathological and clinical concepts, pp. 31–33, Raven Press, New York, 1982
Feniuk W, Humphrey PPA, Watts AD. Presynaptic inhibitory action of 5-hydroxytryptamine in dog isolated saphenous vein. British Journal of Pharmacology 67: 247–254, 1979
Feniuk W, Humphrey PPA, Watts AD. 5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle. European Journal of Pharmacology 96: 71–78, 1983
Fillion GMB, Iluch S, Uvnas B. Release of noradrenaline from the dog heart in situ after intravenous and intracoronary administration of 5-hydroxytryptamine. Acta Physiologica Scandinavica 83: 115–123, 1971
Finch L. Vascular reactivity in hypertensive rats after treatment with antihypertensive agents. Life Sciences 15: 1827–1836, 1974
Fozard JR. Mechanism of the hypotensive effect of ketanserin. Journal of Cardiovascular Pharmacology 4: 829, 1982a
Fozard JR. Basic mechanisms of antimigraine drugs. In Critchley et al. (Eds) Advances in Neurology, Vol. 33. Headache: physiopathological and clinical concepts, pp. 295–307, Raven Press, New York, 1982b
Fozard JR. 5-Hydroxytryptamine in the pathophysiology of migraine. In Bevan et al. (Eds) Vascular neuroeffector mechanisms V, pp. 321–328 Elserier, Amsterdam, 1985
Freedman SB, Chierchia S, Rodriguez-Plaza L, Bugiardini R, Smith G, et al. Ergonovine-induced myocardial ischemia: no role for serotonergic receptors? Circulation 70: 178–183, 1984
Freeman WK, Rorie DK, Tyce GM. Effects of 5-hydroxytryptamine on neuroeffector junction in human pulmonary artery. Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology 51: 693–698, 1981
Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circulation Research 53: 556–573, 1983
Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Annual Review of Pharmacology and Toxicology 24: 175–197, 1984
Gaddum JH. Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. Journal of Physiology (London) 121: 15P, 1953
Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. British Journal of Pharmacology 12: 323–328, 1957
Genefke IK, Garel A, Mandel P. Factors influencing free serotonin in human plasma. Clinica Chimica Acta 20: 61–67, 1968
Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. American Journal of the Medical Sciences 254: 1, 1967
Griffith SG, Lincoln J, Burnstock G. Serotonin as a neurotransmitter in cerebral arteries. Brain Research 247: 388, 1982
Gross MD, Grekin RJ, Gniadek TC, Villareal JZ. Suppression of aldosterone by cyproheptadine in idiopathic aldosternoism. New England Journal of Medicine 305: 181–185, 1981
Haeusler G, Finch L. Vascular reactivity to 5-hydroxytryptamine and hypertension in the rat. Naunyn-Schmiedeberg’s Archives of Pharmacology 272: 101–116, 1972
Halpern A, Kuhn PH, Shaftel HE, Samuels SS, Shaftel N, et al. Raynaud’s disease, Raynaud’s phenomenon, and serotonin. Angiology 11: 151–167, 1960
Hedner T, Persson B, Berglund G. Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension. Clinical and Experimental Hypertension, Part A: Theory and Practice A6: 743–751, 1984
Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL. Augmented responses to vasoconstrictor stimuli in hypercho-lesterolemic and atherosclerotic monkeys. Circulation Research 54: 711–718, 1984
Henry PD, Yokoyama M. Supersensitivity of atherosclerotic rabbit aorta to ergonovine: mediation by a serotonergic mechanism. Journal of Clinical Investigation 66: 306–313, 1980
Holmsen H. Biochemistry of the platelet release reaction. Ciba Symposia, 35: 175–205, 1975
Holtz J, Held W, Sommer O, Kuhne G, Bassenge E. Ergonovine-induced constrictions of epicardial coronary arteries in conscious dogs: alpha-adrenoceptors are not involved. Basic Research in Cardiology 77: 278–291, 1982
Houston DS, Shepherd JT, Vanhoutte PM. Adenine nucleotides, serotinin and endothelium-dependent relaxations to platelets. American Journal of Physiology 248: H389–H395, 1985
Hutton RA, Mikhailidis DP, Bernstein RM, Jeremy JY, Hughes GRV, et al. Assessment of platelet function in patients with Raynaud’s syndrome. Journal of Clinical Pathology 37: 182–187, 1984
Huval WV, Lelcuk S, Shepro D, Hechtman HB. Role of serotonin in patients with acute respiratory failure. Annals of Surgery 200: 166–172, 1984
Huval WV, Mathieson MA, Stemp LI, Dunham BM, Jones AG, et al. Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism. Annals of Surgery 197: 220–225, 1983
Imaizumi Y, Baba M, Imaizumi Y, Watanabe M. Involvement of endothelium in the relaxation of isolated chick jugular vein by 5-hydroxytryptamine. European Journal of Pharmacology 97: 335–336, 1984
Jauernig RA, Moulds RFW. A human arterial preparation for studying the effects of vasoactive agents. Circulation Research 42: 363–368, 1978
Kalsner S, Richards R. Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm. Science 223: 1435–1437, 1984
Kawachi Y, Tomoike H, Maruoka Y, Kikuchi Y, Araki H, et al. Selective hypercontraction caused by ergonovine in the canine coronary artery under conditions of induced atherosclerosis. Circulation 69: 441–450, 1984
Krupp P, Krupp I. Serotonin and toxemia of pregnancy. Obstetrics and Gynecology 15: 237–241, 1960
Kuhn DM, Wolf WA, Lovenberg W. Review of the role of the central serotonergic neuronal system in blood pressure regulation. Hypertension 2: 243–255, 1980
Larsson I, Ahlman H, Bhargava HN, Dahlstrom A, Petterson G, et al. The effects of splanchnic nerve stimulation on the plasma levels of serotonin and substance P in the portal vein of the cat. Journal of Neural Transmission 46: 105–112, 1979
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, et al. Receptor binding profile of R41468, a novel antagonist at 5-HT2 receptors. Life Sciences 28: 1015–1022, 1981
Lindblad LE, Shepherd JT, Vanhoutte PM. Cooling augments platelet-induced contraction of peripheral arteries of the dog. Proceedings of the Society for Experimental Biology and Medicine 176: 119–122, 1984
Lingjaerde O. Platelet uptake and storage of serotonin. In Essman WB (Ed.) Serotonin in health and disease, pp. 139–199, Spectrum, New York, 1977
Luchi RJ, Chahine RA, Raizner AD. Coronary artery spasm. Annals of Internal Medicine 91: 441–449, 1979
Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. Journal of Clinical Investigation 66: 979–986, 1980.
Marwood JF, Stokes GS. Studies on the mechanism of action of the hypotensive effect of ketanserin. Clinical and Experimental Pharmacology and Physiology 11: 125–132, 1984
Maseri A, Pesola A, Marzilli M, Severi S, Parodi O, et al. Coronary vasospasm in angina pectoris. Lancet 1: 713–717, 1977
McCall RB, Schuette MR. Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin. Journal of Pharmacology and Experimental Therapeutics 228: 704–710, 1984
McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. Journal of Clinical Investigation 74: 828–833, 1984
McGrath MA. 5-Hydroxytryptamine and neurotransmitter release in canine blood vessels: inhibition by low and augmentation by high concentrations. Circulation Research 41: 428–435, 1977
Mehta J, Mehta P. Platelet function in hypertension and effect of therapy. American Journal of Cardiology 47: 331–334, 1981
Meuleman TR, Hill DC, Port JD, Stanley TH, Pace NL, et al. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction. Critical Care Medicine 11: 606–611, 1983
Mohan J. The neurosurgeon’s view. In Boullin (Ed.) Cerebral vasospasm, pp. 15–35, John Wiley and Sons, Chichester, 1980
Moulds RFW, Iwanov V, Medcalf RL. The effects of platelet-derived contractile agents on human digital arteries. Clinical Science 66: 443–451, 1984
Muller-Schweinitzer E, Engel G. Evidence for mediation by 5-HT2 receptors of 5-hydroxytryptamine-induced contraction of canine basilar artery. Naunyn-Schmiedeberg’s Archives of Pharmacology 324: 287–292, 1983
Nagai H, Noda S, Mabe H. Experimental cerebral vasospasm. Part 2: Effects of vasoactive drugs and sympathectomy on early and late spasm. Journal of Neurosurgery 42: 420–428, 1975
Nevelsteen A, De Clerck F, Loots W, De Gryse A. Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist. Interntional Archives of Pharmacodynamics and Therapy 270: 268–279, 1984
Nielson SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud’s phenomenon. European Journal of Clinical Pharmacology 24: 421–423, 1983
Ohta T, Osaka K, Siguma M, Yamamoto M, Shimizu K, et al. Cerbral vasospasm following ruptured intracranial aneurysms, especially some contributions of potassium ion released from subarachnoid hematoma to delayed cerebral vasospasm. In Bevan SA et al. (Eds) Vascular neuroeffector mechanisms, 4th International Symposium, pp. 353–358, Raven Press, New York, 1983
Ojemann RG, Crowell RM. Surgical management of cerebrovascular disease, pp. 128–140, Williams and Wilkins, Baltimore, 1983
Page IH. Serotonin (5-hydroxytryptamine). Physiological Reviews 34: 563–588, 1954
Page IH, McCubbin JW. The variable arterial pressure response to serotonin in laboratory animals and man. Circulation Research 1: 354–362, 1953
Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of 3H-5-hydroxytryptamine, 3H-lysergic acid diethylamide and 3H-spiroperidol. Molecular Pharmacology 16: 687–699, 1979
Peroutka SJ, Noguchi M, Tolner DJ, Allen GS. Serotonin-induced contraction of canine basilar artery: mediation by 5-HT1 receptors. Brain Research 259: 327–330, 1983
Rapport MM. Serum vasoconstrictor (Serotonin) V: presence of creatinine in the complex; a proposed structure of the vasoconstrictor principle. Journal of Biology and Chemistry 180: 961–969, 1949
Raskin NH. Pharmacology of migraine. Annual Review of Pharmacology and Toxicology 21: 463–478, 1981
Reinhard JF, Liebmann JE, Schlosberg AJ. Serotonin neurons project to small blood vessels in the brain. Science 206: 85–87, 1979
Roddie IC, Shepherd JT, Whelan RF. The action of 5-hydroxytryptamine on the blood vessels of the human hand and forearm. British Journal of Pharmacology 10: 445–450, 1955
Rydzewski W. Serotonin (5-HT) in migraine:levels in whole blood in and between attacks. Headache 16: 16–19, 1976
Salmon S, Bonciani M, Fanciullacci M, Marianelli L, Michelacci S, et al. A putative 5-HT central feedback in migraine and cluster headache attacks. In Critchley et al. (Eds) Advances in neurology, Vol. 33. Headache: physiopathological and clinical concepts, pp. 265–274, Raven Press, New York, 1982
Saper JR. Migraine: I. Classification and pathogenesis. Journal of the American Medical Association 239: 2380–2383, 1978
Sasaki T, Wakai S, Asano T, Takakura K, Sano K. Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. Journal of Neurosurgery 57: 74–82, 1982
Saxena PR. Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. European Journal of Pharmacology 27: 99–105, 1974
Schaub RG, Meyers KM, Sande RD. Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis. Journal of Laboratory and Clinical Medicine 90: 645–653, 1977
Schroeder JS, Bolen JL, Quint RA, Clark DA, Hayden WG, et al. Provocation of coronary spasm with ergonovine maleate. American Journal of Cardiology 40: 487–491, 1977
Seibold JR, Jageneau AHM. Treatment of Raynaud’s phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis and Rheumatism 27: 139–146, 1984
Senior JB, Fahim I, Sullivan FM, Robson JM. Possible role of 5-hydroxytryptamine in toxaemia of pregnancy. Lancet 2: 553–554, 1963
Shafer AI, Crawford DD, Gimbrone MA. Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. Journal of Clinical Investigation 73: 1105–1112, 1984
Sibbald W, Peters S, Lindsay RM. Serotonin and pulmonary hypertension in human septic ARDS. Critical Care Medicine 8: 490–494, 1980
Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. International Archives of Allergy 19: 55–58, 1961
Sjaastad O. The significance of blood serotonin levels in migraine: a critical review. Acta Neurologica Scandinavica 51: 200–210, 1975.
Somerville BW. Platelet-bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology 26: 41–45, 1976
Spatz M. Serotonin in cardiac disease. In Essman WB (Ed.) Serotonin in Health and Disease, Vol. V, Clinical applications, pp. 389–401, Spectrum, New York, 1979
Speight TM, Avery GS. Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 3: 159–203, 1972
Stranden E, Roald OK, Krohg K. Treatment of Raynaud’s phenomenon with the 5-HT2-receptor antagonist ketanserin. British Medical Journal 285: 1069–1071, 1982
Strum JM, Junod AF. Radioautographic demonstration of 5-hydroxytryptamine-3H uptake by pulmonary endothelial cells. Journal of Cell Biology 54: 456–467, 1972
Tada M, Kuzuya T, Inoue M, Kodama K, Mishima M, et al. Elevation of thromboxane B2 levels in patients with classic and variant angina pectoris. Circulation 64: 1107–1115, 1981
Tell GP, Fozard JR, Schechter PJ, Centonze V, Beorchia S, Loisy C. Controlled study of MDL 72222, an antagonist at neuronal 5-HT receptors, in the symptomatic treatment of migraine. British Journal of Pharmacology, abstract, in press, 1984
Thompson JH. Serotonin and the alimentary tract. Research Communications in Chemical Pathology and Pharmacology 2: 687–782, 1971
Thompson JH. Serotonin (5-hydroxytryptamine) and the alimentary system. In Essman (Ed.) Serotonin in Health and Disease, Vol. 4, pp. 201–392, Spectrum, New York, 1977
Todd MH, Forrest JB, Cragg DBJ. The effects of aspirin and methysergide on responses to clot-induced pulmonary embolism. American Heart Journal 105: 769–776, 1983
Turpie AGG, de Boer AC, Genten E. Platelet consumption in cardiovascular disease. Seminars in Thrombosis and Hemostasis 8: 161–185, 1982
Utsunomiya T, Krausz MM, Shepro D, Hechtman HB. Prostaglandin control of plasma and platelet 5-hydroxytryptamine in normal and embolized animals. American Journal of Physiology 241: H766–H771, 1981
Van der Starre PJA, Scheijgrond HW, Reneman RS, Rolling JB. The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery. Anesthesia and Analgesia 62: 63–69, 1983
Vanhoutte PM. 5-Hydroxytryptamine, vasospasm, and hypertension. In De Clerck and Vanhoutte (Eds) 5-Hydroxytryptamine in peripheral reactions, pp. 163–174, Raven Press, New York, 1982
Vanhoutte PM. Peripheral serotonergic receptors and hypertension. In Vanhoutte PM (Ed.) Serotonin and the cardiovascular system, pp. 125–133, Raven Press, New York, 1985
Vanhoutte PM, Shepherd JT. Effect of temperature on reactivity of saphenous, mesenteric, and femoral veins of the dog. American Journal of Physiology 218: 187–190, 1970
Vanhoutte PM, Van Nueten JM, Symoens J, Janssen, PAJ. Antihypertensive properties of ketanserin (R41468). Federation Proceedings 42: 182–185, 1983
Vanhoutte PM, Rimele TJ. Role of the endothelium in the control of vascular smooth muscle function. Journal of Physiology (Paris) 78: 681–686, 1983
Van Nueten JM, Janssen PAJ, Van Bek J, Xhonneux R, Verbeuren TJ. et al. Vascular effects of ketanserin (R41468), a novel antagonist of 5-HT2 serotonergic receptors. Journal of Pharmacology and Experimental Therapeutics 218: 217–230, 1981
Van Nueten JM, Janssen PAJ, De Ridder W, Vanhoutte PM. Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R41468). European Journal of Pharmacology 77: 281–287, 1982
Van Nueten JM, Leysen JE, De Clerck F, Vanhoutte PM. Serotonergic receptor subtypes and vascular reactivity. Journal of Cardiovascular Pharmacology 6: S564–S574, 1984
Verheyen A, Vlaminckx E, Dauwers F, Van Den Broeck C, Wouters L. Serotonin-induced blood flow changes in the rat hind-legs after unilateral ligation of the femoral artery. Inhibition by the S2 receptor antagonist ketanserin. International Archives of Pharmacodynamics and Therapy 210: 280–294, 1984
Voldby B, Engbaek F, Enevoldsen EM. CSF serotonin concentrations and cerebral arterial spasm in patients with ruptured intracranial aneurysm. Stroke 13: 184–189, 1982
Webb RC. Increased vascular sensitivity to serotonin and methysergide in hypertension in rats. Clinical Science 63: 73s, 1982
Weiner CP, Socol ML, Vaisrub N. Control of preeclamptic hypertension by ketanserin — a serotonin receptor antagonist. American Journal of Obstetrics and Gynecology, 149: 496–500, 1984
Wenting GJ, Woittiez AJJ, Manin’t Veld AJ. Schalekamp MADH. 5-HT, alpha-adrenoceptors, and blood pressure: effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6: 100–109, 1984
Whigham KAE, Howie PW, Drummond AH, Prentice CRM. Abnormal platelet function in pre-eclampsia. British Journal of Obstetrics and Gynaecology 85: 28–32, 1978
White RP, Shirasawa Y, Robertson JT. Comparison of responses elicited by alpha-thrombin in isolated canine basilar, coronary, mesenteric, and renal arteries. Blood Vessels 21: 12–22, 1984
Winkelmann RK, Goldyne ME, Linscheid RL. Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. British Journal of Dermatology 95: 51–56, 1976
Zervas NT, Candia M, Candia G, Kido D, Pessin MS, et al. Reduced incidence of cerebral ischemia following rupture of intracranial aneurysms. Surgical Neurology 11: 339–344, 1979
Zervas NT, Kuwayama A, Rosoff CB, Salzman EW. Cerebral arterial spasm: modification by inhibition of platelet function. Archives of Neurology 28: 400–404, 1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Houston, D.S., Vanhoutte, P.M. Serotonin and the Vascular System. Drugs 31, 149–163 (1986). https://doi.org/10.2165/00003495-198631020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198631020-00004